Faculty Strategic Plan

)(2010 2015
SWOT Analysis
12
23
24
29
31
35
36
37
43
45
59
60
61
68
69

23 1995
1995 / 1994

.
) 2 (

.

2004/2005
.
2004 CIQAP
.
" "
CIQAP
.

) (.
)
( ) (

:
4

.
:
:

.

.

.

, .

, ,,

,
,

.
:
5

-1

:
-1
-2
-3

-2
.

-3

33% / 51
32.5% / 50
10% / 16
20% / 31
4.5% / 7

-4

40% / 17
14.5% / 6
12% / 5
9.5% / 4
7% / 3
14.5% / 6
2.5% / 1

-5

.
205
-6
.19/10/2009
:
-1

.
-2 5 .
SWOT Analysis

.

:
-1
.

-2
.

-3

34.5% / 18
27% / 14
7.5% / 4
17.5% / 9
13.5% / 7

-4

40% / 17
14.5% / 6
12% / 5
9.5% / 4
7% / 3
14.5% / 6
2.5% / 1

-5
.

-6
.
205
-7
.19/10/2009
:

.
:Strengths
2008 .2012
10
:Weaknesses
..
11
:

.
: Opportunities
DAAD) Deutscher Akademischer Austausch

(Dienst (Deutsche Forschungsgemeinschaft (DFG
:Threats
:
-1
-2
-3
-4

12
-5
-6
-7
:
-1
-2
-3
-4
-5

-:
-1 :
)(

2008 .2012
)(

13
90
%
90
%
85
%
90
%
95
%
60
%
65
%
35
%
30
%
30
%
30
90%
0.81
90%
0.81
85%
0.72
95%
0.86
95%
0.9
0.1
5
0.1
5
0.1
3
0.1
6
0.1
7
40%
0.24
45%
0.29
60%
0.21
0.0
4
0.0
5
0.0
4
65%
0.19
50%
0.15
55%
0.16
0.0
4
0.0
3
0.0
5.34
3
1.0
0
-2 :
)(
2008
.2012
0.1
5
0.1
5
0.1
3
0.1
6
0.1
7
0.6
0.45
0.26
0.64
0.85
0.04
0.05
0.04
0.04
0.03
0.03
)(
.
14
0.0
4
0.0
5
0.0
4
0.0
4
0.0
3
0.0
3
1.0
0
15
3.00
-3 :

3
3
2
3
3
3
3
3
3
3
2
3
3
2
2
2
2
3
2
2
2
2
2
2
2
2
2
2
110
0
1111110
110
) : - -(
) : - -(
) :-(
16
-:
-1 :
)(
DAAD DFG

.

.
85%
0.1 0.43
50
%
60
%
65
%
65
%
65%
0.0 0.39
9
0.1 0.45
1
0.1 0.45
1
90
%
90%
0.1 0.81
9
85
%
40%
0.0 0.34
8
60
%
90
%
55
%
65
%
50%
0.30
40%
0.36
60%
0.33
50%
0.33
0.0
7
0.0
8
0.0
8
0.0
8
70%
70%
)(

.

.
.

1.0 4.19
0
17
-2 :
)(
DAAD DFG
)(

.
.
0.30
0.36
0.22
0.44
0.38
0.0
8
0.16
0.0
7
0.0
8
0.0
8
0.0
8
0.21
0.16
0.32
0.40
0.1
0.0
9
0.1
1
0.1
1
0.1
9
1.0
0
18
2.95
19
SWOT
)(S
.
.

.

2008 .2012
SWOT
)(W
)O

.
DAAD DFG

.

.
)) (S + O (
.1

.
.2

.
.3
.
.4
.
)) (W + O (
.1 .
.2

.
.3
.
.4
.
.5
.
.5
)(T
2,3

.

.

.

)) (S + T (
.1 .
.2
.
.3 .
.6

.
.7 .
)) (W + T(
.1 .
) (

.1
.2
) 57357 . (3
.3
P C R
.
.4 :

) .(4
-
) .(5

.
.5 " "
.
.6 .
.7
-2010
.2011

:
:
:
:
:
:
:
:
.1
.2
.3
.4
:
.1
.2
.3
.4
.5

) (NARS .

.
.
.6
.7
.8
.9
.10
.11
.12
.13
.14
.15
.16

.
.

.
-1
-1
.
-2
.
-3
) (NARS
-2

.
.
-4
.
-5 .
-6
.
-7
-8 .
-9
.
-10
.
-3 -11 .
-12 .
-13 .
.
-14
.
-4 -15
-16
.
:

-1
:
-1
-2

-3
.

-2
.

-3

55% / 18
9% / 3
12% / 4
6% / 2
18% / 6
211
-4
.11/1/2010
:

-1
:
-1
-2
-3
-4

-1
.

-2

65.5% / 23
14.5% / 5
5.5% / 2
14.5% / 5
211
-3
.11/1/2010
:
-1
.

-1
.

.
-2
.
.
.
-4

4
.
:

:

NARS
% 25 20
25%
% 45 40
35%
% 23 17
17%
%84
12%
% 10 5
6%
%52
2%
%52
3%
:
:
) (

: :

.
:

.
-1

.
-2
-3
-4
-5
-6
) 218
(31/5/2010
-7 .
:
-1
-2
:
-1

-2

-3

) -:( Objectives
-1

-2
-3
.
-4
.
-5
.
-6

-7
.
) -:(policies
-1
-2
) (Impact Factor
-3

.
-4
.
-5
.
) -: (Action plan
-1
-2

.
-3

-4
.
-5
-: (Responsibilities ) -:
-1
. /
-2

-3
.
) (
-4
.
) -:(Funding
-1
-2
CIQAP
-3

.
.
-4
) -:(Indicators
-1
-2
-3
.
7
-4
.
-5
-6
.
-:(Research items ) -:
:

.
Under the theme of towards Safe and active of drugs
. / / /
Production of new drug delivery systems treatment of gnendisfunction related diseases and DNA vaccination as part of
.cooperation in biotechnological field
Production of different dosage forms carrying drugs and measuring the clinical efficacy of these forms on volunteers.
Comparing the newly produced dosage forms to what available in
.market regarding bioavailability, clinical efficacy and toxicity
Quantitative estimation of natural compounds in pharmaceutical .products, stability and bioequivalence standards
.Pharmaceutical effects of gum Arabic Biological activities of medicinal plants pure compounds and its .extracts
Antimicrobial activities of pure compounds and medicinal plant extracts
Mutagenicity and carcinogenicity of medicinal herbal plant .extracts
Genetic manipulation of medicinal plants to enhance or modulate .the production of important active constituents
.
.
.
Applied and Environmental Microbiology: the department aims to study the environmental risks and hazards on the surrounding
society in the Helwan area, which serves a large sector of the
population in Helwan governorate. Currently, a research project
.deals with the microbiological analysis of drinking water
Biotechnology: this field of research utilizes bacteria like Escherichia coli to produce valuable pharmaceutical products with
the least costs possible. The results of research studies can be
applied in industry to produce the desired product on the industrial
scale. The research work accomplished in a master's thesis
optimized the fermentation conditions that could be applied to
.increase the production of liquid crystalline polymers
Clinical and pharmaceutical microbiology: the department is interested in studying the rates of bacterial resistance to antibiotics
in the clinical settings (public hospital in Helwan and teaching
hospitals in other areas in Cairo). The outcome of research studies
will help determine the reason of treatment failure using antibiotics
(elucidate the mechanism of bacterial resistance to antibiotics). As
a result, clinicians will be able to decide what appropriate
treatment regimen to be used; thus reduce healthcare costs and
economic burden on the healthcare sector. Knowing the effective
treatment helps alleviate the pain and suffering of patients and
upgrade the status of public health. A master's thesis recently

finished in the department has recommended treatment options ad
infection control guidelines to be implemented at the National
.Heart Institute in Cairo
Immunology: the department carries out research projects in collaboration with VACSERA, Cairo, Egypt to develop vaccines
(e.g. diphtheria antitoxin). This has an important impact on the
public healthcare. Other research projects in immunology and its
relation to pharmacy are being conducted in collaboration with a
.university in England
Collaborative research with Pharmaceutical chemistry and organic chemistry departments to screen newly synthesized
.compounds with possible antimicrobial or antiviral activity
The department also coordinates with Pharmaceutics department in area s of drug delivery system, as well as drug formulation of
.biotechnological products such as vaccines
-1

.
. ) ( -2
-3
.
-4 .
-5 .
-6
.
-7
.
-8 .
-9
.
-10 )
213 .(15/2/2010
-11
:
-1
-
-2 .

2008/2012
:
.1
.
.2
.
.3
.
.4
.
.5
:

.

.
:

:
.1

.
.2 .
.3 .
.4
.5
.6
.
.1
.2
.3
.4
.1 .
.2
.
:
.1
.2
2008
2012

.2

.1

2008/2009
2008/20012
- 1
2008/2009
+

.2
+

+
- 2
2008/2010

.
) 3

2008/2009
(.

+
- 3
2008/2009
.4
2008

- 4
2008/2010

2008/2012

+ +

.5
.
2008/20122008/2012

.
.6
.5
+ +

2008/2012

.7

2008/2012
.
.6
+ +

2008/2012
.8
2008/2012

+ +
.7

:
: :

:
.1
.2
.3
.4
.5
.6
.7
.8

.
)
----(
.

.
.
.

.

.
: :
.1
.2
.3
.4
.5
.6
.7
.8
.
.
.

.

.
.
. Data Show
.1 .
.2 .
.3
.4 .
.5
.
:

:
.1
.2
.3
.4
.5
.6
.7
.8

2008
2009
3
.1
)
+
(
.2

.3

.4

2010
1 4 3
2011
2012
4 3 21 4 3 2 1 4 3 2
-2008
2012
200,000
+
(

-2008
2008
150,000
-2008
2010
500,000

+ +

-2008
2010
400,000
-2008

+ + 2012

250,000
-2008

+ + 2012

150,000
-2008

+ + 2012

+

+
+

+

+
+

+

+
-2008
2009
100,000

100,000
-2008
2012
125,000
-2008
2009
65,000
+

+
+

+

+
+

+

+
+

+

+
+
-2008
2010
30,000
-2008
2010
24,000
-2008
2010
100,000
-2008
2012
150,000
1,750,000
1,594,000
3,344,000
+

+
+

-2008
2012
1,000,000
:

.1

.2

.3
.

.4
.
.
.5
.
.6

.7
.
.
.8

.9
.
:
-1
)
(
)
(-
-2

:
-1

-2

-3

.
:
.1

.

:

.
.2

.
.3

.
.4

.
.5

:
-1
-2

.
.6

2010 - 2015
- :
1
1
0
20
20
20
20
20
20
20
20
20
20
2010
2011
2011
2012
2012
2013
2013
2014
2014
2015
**

:

.
)

( .
2012

:

-1

) (SWOT
.

-2
.

-3
.
1/1

.
1/2

CIQA
P
-1
11/1/ - 1

-2

-2

-1
1/1/2

-2
-3
-3

-4

-1
1/2/1 -1
13

CIQAP

%40

-2
.
3
-1
-2
-3
-4

-1
-2
-3
-4
-2011
2011
75,000
25,000
2010
2011
2010
- 2011
-2011
2012
5,000
5,000
3,893,000
2,343,0
00
1,550,000
900,000
900,000

50,00
0
-3
4

1,200,000
-2012
2013
1,200,0
00
1/2/2

.
1/2/3

.
1/2/4

-1
-2
-3
-4
-1

%30
-1
-2
-3
-4
-5
-6
-7 CIQAP
2010
2011
-1
-2
-3
-4

-1 -1
-2

-3
10
-4
-2011
2013
-1
-2
-1

-1
-2
150,000
150,00
0
300,000
200,00
0
100,00
0
Double
Course
2010
- 2012
75,000
-3
-4

-3
-4
40,00
0
35,00
0
1/2/5

-1
-2
-3
-4
-1
%20
-2

%20
-3

-1
-2

-3
-2010
2011
1/2/6

-1

-2

.
-1

%15
-1
-2

-3
-2011
2011
1/2/7

-1
-2
-3
-1

%10
-1
-2
-3

-4
2,000
2,000
50,000
40,00
0
10,00
0
-2011
2011
20,000
20,00
0
1/3

)
(NARS

1/2/8

-1
-2
-3
-4
-1

-2
-3

-4

-5
-6

-7

-8

-9
-10
-11

-1
-2
-3

-4
-2010
2011
1/3/1

)
(NARS
-1
-2
-3
-4
-5
-1

-2
-3
.
-1
-2
-3
-4
-2011
2011
50,000
14,50
0
35,500
20,000
)
(NARS

-5
-6
20,00
0
-1

CDC
-1
-2
-3
-4
-5 CDC
2011
- 2012
1/3/2 -1
-2

-3

1/3/3

)

(
-1
-2
-3
-4

-1
CDC
-1
-2
-3
-4
-5 CDC
-2010
2011
1/3/4

-1
-2
-1

-1
-2
-3
-2011
2011
20,000
20,00
0
Double
Course
10,000
10,00
0
10,000
-3
-4

-1
-2
-3
-4
-4
-1
%5
-2

%20
-1
-2
-3
-4
-2011
2012
50,000
-1
-2
-3
-4

-5
-2011
2012
50,000
-1
-2
-3
-4
-2011
2012
1/4

1/4/1

1/5

.
1/5/1 -1
-2

-3
-4
-1
%10
-2
-3
-1
-2
-3
-4
-1

.
-2

CIQAP
10,00
0
50,00
0
10,00
0
40,00
0
1/5/2

100,000
70,00
0
30,000

1/5/3

-1
-2
-3
-4
-1
-2
-3

1/5/4
-1

-1 10
-1
-2

-3
-4
-5

-2012
-1
-2
2014
-2010
2012
100,000
70,00
0
30,000

5,0001
5,0001

1/6

)
(.Pharm.D
)
(.Pharm.D
1/5/5

-1
-2
-3
-1
-1
-2
-3
-4
2010
- 2011
1/6/1

)
(.Pharm.D
-1
-2
-3
-4
-5
-6
-1
-2
%5
-1
-2
-3
-4
-2012
2012
5,000
5,000
50,000
50,00
0
1/6/2
.
-7
-8
.
-1
-2
-2013
2013

5,000
5,000

7,155,000
2,904,
500
2,585,
500
:
.
1,665,0
00
3/10

.

CIQAP
3/10/1
.

.
3/10/2

-1
-2
-3
-4
-5
-1
-2
-1 -1
-2

-3
-4
-2012
2012
-1
-2
-2012
-1

5,000
2,000
3,000
5,000
3/11

3/10/3

- 1
-2
-3
-4
-5
-1
.
-1
-2
-3
-4
-2010
2011
3/10/4

-1
-2
-3
-4
-5
-1
-2
-3
-4

-1
-2
-3
-4
-2010
2011
3/11/1

.
-1
-2
-3
-4

-5
-6
-1

-2

-1
-2
-3
-4
-2010
2013
2,000
3,000
10,000
10,000
10,000
10,000
30,000
10,000
10,00
0
10,00
0

3/12

3/12/1 -1
-2

-3
-4
-1
-1
-2
-3
-4
-2012
2013
-1
-2
-3
-4
-1

%10
-1
-2
-3
-4
-2013
2014
10,000
3/12/3 -1
-2

-3

-4
-5

-1

%10
-2

-3
-1

%10
-2
-1
-2
-3
-4
-2013
2014
5,000
-1
-2
-3
-2013
2014
3/12/2

3/12/4 -1
-2

-3
50,000
50,00
0
10,00
0
5,000
5,000
-4
-5

-3
-4
-1
-2
-3
-4
3/12/6 -1
-2
-3
-4
-1

.
-1
-2
-3
-4
-1
-2
-3
-4
-1
-2
-3
-4
-1
-2
-3
-4
3/12/5

3/13

.
3/13/1 -1
-2

-3

-4
3/13/2 -1
-2

-3

-4 .
-5
-1
-1
-2
-1

%10
-2

-3
5,000
-2013
2013
3,000
-2013
2013
5,000
-2012
2013
3,000
-2013
2014
5,000
3,000

5,000

3,000
5,000

3/13/3 -1
-2

-3
-4
-5
3/13/4 -1
-2
-3
-4
3/14

-1

%10
-2

-3
-1
.
3/14/1

-1
-2
-3
-4

-1
%10
3/14/2

-1
-2
-3
-4

-1

%10
-1
-2
-3
-4
-2013
2014
-1
-2
-3
-4
-1
-2
-3
-4
-2013
2013
5,000
-2013
2014
10,000
-1
-2
-3
-4
3,000
3,000
5,000

10,00
0
-2013
2014
5,000
5,000

169,000
30,00
0
87,00
0
52,00
0
4/15

.

CIQAP
4/15/1

-1
-2
-3
-4
-5
-1

-2

%20
-1
-2
-3
-4
-5
-2011
2012
5,000
6,000
1,000
4/15/2

4/16

-1
-2
-3
-4
-5
- 1
4/15/3

-2

-3

-4
-5
-1
4/16/1

-2
-3
4/16/2 -1

-2
-3
-1

-1
-2
-3
-4
-5
-2011
2012
-1

.
-1
-2
-3
-4
-2011
2011
-1

%20
-1
-2
-3
-4
-5
-1
-2
-3
-4
-5
-2011
2011
-1

6,000
5,000
1,000
3,000
3,000
3,000
3,000
-2012
2012

5,000
5,000
/4/163

-1
-2
-3
-4
-1
-2

-3

%20
-1
-2
-3
-4
-5
-2010
2011
10,000
10,000
33,000

26,000
2,000
5,000
7,500,000
3,025,
500
2,722,
500
1,752,
000

Faculty Strategic Plan

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Faculty Strategic Plan

Uploaded by

Copyright:

Available Formats

)(2010 2015

DAAD) Deutscher Akademischer Austausch

upgrade the status of public health. A master's thesis recently

You might also like